MINISTER OF THE STATE IN THE MINISTRY OF HEALTH & FAMILY WELFARE (SHRI DINESH TRIVEDI)
(a) to (c): The Drug Technical Advisory Board (DTAB), a statutory body under the Drugs and Cosmetics Act
examines the safety issues related to continued marketing of certain drug formulations, in context of
current knowledge, which have been withdrawn/restricted in some other countries. Certain drugs or
formulations withdrawn in one or some countries are continued to be marketed in India after examination
by the Expert Committees set-up under DTAB, and wherever necessary, restrictions are imposed on their
use for certain indications only. These are based on the risk assessment process which includes disease
pattern in the country, indications and dosage of the drug permitted, availability of safe substitutes
and overall safety profile of the drug.
(d) & (e): Safety issues of continued marketing of certain drug formulations such as nimesulide, Gatifloxacin,
Tegaserod, rosiglitazone etc, in context of current knowledge, which have been withdrawn / restricted in some
other countries are under examination by Drug Technical Advisory Board (DTAB). Details of companies who are
manufacturing these drugs are not available with Central Drugs Standard Control Organisation (CDSCO) as the
manufacturing licence is granted by State Licencing Authority. However as per available information nimesulide
is marketed by Dr.Reddys Labs, Piramal Lifesciences, Alembic etc., Gatifloxacin by Aristo Pharma, Torrent
Pharm, Piramal, Cipla Ltd etc., Tegaserod by Emcure, Torrent, Intas etc., rosiglitazone by Dr. Reddys,
Torrent, Emcure, Cipla etc.